GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » EV-to-EBIT

Journey Medical (Journey Medical) EV-to-EBIT : -31.46 (As of May. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Journey Medical's Enterprise Value is $60.84 Mil. Journey Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.93 Mil. Therefore, Journey Medical's EV-to-EBIT for today is -31.46.

The historical rank and industry rank for Journey Medical's EV-to-EBIT or its related term are showing as below:

DERM' s EV-to-EBIT Range Over the Past 10 Years
Min: -44.09   Med: -1.18   Max: -0.21
Current: -31.46

During the past 5 years, the highest EV-to-EBIT of Journey Medical was -0.21. The lowest was -44.09. And the median was -1.18.

DERM's EV-to-EBIT is ranked worse than
100% of 666 companies
in the Drug Manufacturers industry
Industry Median: 17.81 vs DERM: -31.46

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Journey Medical's Enterprise Value for the quarter that ended in Dec. 2023 was $98.60 Mil. Journey Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.93 Mil. Journey Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.96%.


Journey Medical EV-to-EBIT Historical Data

The historical data trend for Journey Medical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical EV-to-EBIT Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -1.27 -0.91 -50.98

Journey Medical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.91 -0.93 -0.84 -2.62 -50.98

Competitive Comparison of Journey Medical's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Journey Medical's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Journey Medical's EV-to-EBIT falls into.



Journey Medical EV-to-EBIT Calculation

Journey Medical's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=60.841/-1.934
=-31.46

Journey Medical's current Enterprise Value is $60.84 Mil.
Journey Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Journey Medical  (NAS:DERM) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Journey Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-1.934/98.596664
=-1.96 %

Journey Medical's Enterprise Value for the quarter that ended in Dec. 2023 was $98.60 Mil.
Journey Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Journey Medical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Journey Medical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus

This Insider Just Sold Shares of Journey Medical Corp

By GuruFocus Research GuruFocus Editor 05-20-2023